Match!

Key factors in the rising cost of new drug discovery and development

Published on May 1, 2004in Nature Reviews Drug Discovery57.62
· DOI :10.1038/nrd1382
Michael Dickson10
Estimated H-index: 10
(USC: University of South Carolina),
Jean Paul Gagnon2
Estimated H-index: 2
(Aventis Pharma)
Abstract
The development of a new drug requires a major investment of capital, human resources and technological expertise. It also requires strict compliance with regulations on testing and manufacturing standards before a new compound can be used in the general population. All these requirements contribute to the cost increases for new chemical entity (NCE) R&D. The central question raised by this trend is: who in the future will pay for new pharmaceutical R&D? With this question in mind, this article first describes how the environment for pharmaceutical RD second, reviews the literature on the cost of drug discovery and development for NCEs; and third, considers the societal value of new drugs. The development of a new drug requires a major investment of capital, human resources and technological expertise. It also requires strict compliance with regulations on testing and manufacturing standards before a new compound can be used in the general population. All these requirements contribute to the cost increases for new chemical entity (NCE) RD second, reviews the literature on the cost of drug discovery and development for NCEs; and third, considers the societal value of new drugs.
  • References (30)
  • Citations (257)
References30
Newest
#1Joseph A. DiMasi (Tufts Center for the Study of Drug Development)H-Index: 26
#2Ronald W. Hansen (UR: University of Rochester)H-Index: 7
Last.Henry G. Grabowski (Duke University)H-Index: 39
view all 3 authors...
#1Henry G. Grabowski (Duke University)H-Index: 39
#2John Vernon (Duke University)H-Index: 17
Last.Joseph A. DiMasi (Tufts University)H-Index: 26
view all 3 authors...
Cited By257
Newest
#1Akihito Nozaka (Ridai: Tokyo University of Science)H-Index: 1
#2Ayaka Nishiwaki (Ridai: Tokyo University of Science)
Last.Hayao Taguchi (Ridai: Tokyo University of Science)H-Index: 17
view all 12 authors...
#1Ping Xuan (Heilongjiang University)H-Index: 1
#2Yangkun Cao (Heilongjiang University)
Last.Tonghui Shen (Heilongjiang University)
view all 6 authors...
#1Mohammad Arafat (UniSA: University of South Australia)
#2Paris Fouladian (UniSA: University of South Australia)
Last.Sanjay Garg (UniSA: University of South Australia)
view all 6 authors...
#1Qi Zhao (SAU: Shenyang Aerospace University)H-Index: 1
#2Haifan Yu (Liaoning University)H-Index: 1
Last.Xing Chen (CUMT: China University of Mining and Technology)H-Index: 28
view all 5 authors...
View next paperCan the pharmaceutical industry reduce attrition rates